Clinical Trial

Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This is a multi-centered, randomized, open-label, parallel, phase IV clinical trial comparing the effectiveness and cost-effectiveness of oral multi-dose metronidazole (MTZ) and oral single-dose secnidazole (SEC) for the treatment of Trichomonas vaginalis in both women and men.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-02-07; most recent amendment 2026-05-04.
Status change: Not Yet Recruiting → Recruiting 2025-06-03
Trial Details
NCT Number NCT06261840
Lead Sponsor Tulane University
Collaborators: University of Alabama at Birmingham, Louisiana State University Health Sciences Center in New Orleans, Healthcare Clinical Data
Conditions Trichomonas Vaginitis, Bacterial Vaginitis
Enrollment 1,200 participants
Start Date 2025-05-06
Primary Completion 2029-05-01 (estimated)
Study Completion 2029-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-06